Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Established in June 1993, Introgen is a leading developer of gene-therapy products for the treatment of cancer. The company is capitalising on the significant advances in the understanding of the human genome and the role that genetic function plays in the development of cancer and other diseases. According to Introgen, its drug-discovery and development programmes have resulted in innovative approaches by which physicians use genes to treat cancer and other diseases.